SCHEMBL6560465

SCHEMBL6560465

CCc1ccccc1N1CCN(C(=O)Nc2nc(C)c(C)nc2OC)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
RAB9A P51151 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTR1A P08908 2/20 0.43
HTR1D P28221 2/20 0.43
HTR1B P28222 2/20 0.43
GAA P10253 3/20 0.43
HTR7 P34969 2/20 0.43
ALDH1A1 P00352 2/20 0.43
RBP4 P02753 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR6 P50406 1/20 0.43
PKM P14618 1/20 0.42
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6560430 0.89 KMT2A (0.44) MAPTRAB9ATRPV1KMT2AL3MBTL1
SCHEMBL6561276 0.88 KMT2A (0.52) KMT2AALDH1A1LMNAPKMMEN1
SCHEMBL6560608 0.88 MAPT (0.60) MAPTRAB9AKMT2AHTR1AHTR1D
SCHEMBL6559632 0.87 KMT2A (0.60) MAPTRAB9AKMT2AL3MBTL1HTR1A
SCHEMBL6559625 0.85 MAPT (0.44) MAPTRAB9ATRPV1KMT2AL3MBTL1
SCHEMBL6559708 0.85 KMT2A (0.46) MAPTRAB9ATRPV1KMT2AL3MBTL1
SCHEMBL6561018 0.84 RBP4 (0.52) MAPTKMT2AL3MBTL1HTR1AHTR1D
SCHEMBL6559720 0.80 MAPT (0.39) MAPTRAB9AKMT2AL3MBTL1HTR1A
SCHEMBL6562222 0.80 MAPT (0.47) MAPTKMT2AL3MBTL1GAALMNA
SCHEMBL8705064 0.79 HTR1A (0.52) MAPTRAB9ATRPV1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100354271-C Piperazine derivatives and process for the preparation thereof SAMJIN PHARM CO LTD (KR) 2007-12-12 CN disclosed
EP-1075469-B1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2004-05-26 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS MAPT 4877/4885RAB9A 2925/4885TRPV1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.